Nucleotide reverse transcriptase inhibitor
Tenofovir disoproxil
Brand names: Viread
Adult dose
Dose: 245mg PO OD
Route: PO
Frequency: OD
Dose adjustments
Renal
Reduce / avoid in renal impairment
Clinical pearls
- HIV (with other ARVs); HBV; HIV PrEP (with emtricitabine)
- TAF preferred where available
Contraindications
- Severe renal impairment
- Hypersensitivity
Side effects
- Renal impairment
- Fanconi syndrome
- Bone demineralisation
- Lactic acidosis (rare)
- HBV reactivation if stopped
Interactions
- NSAIDs
- Other nephrotoxic drugs
- Didanosine (avoid)
Monitoring
- U&E
- Phosphate
- DEXA
Reference: BNF; BHIVA; NICE TA481; https://bnf.nice.org.uk/drugs/tenofovir-disoproxil/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023